CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings

Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Todorovic, Zeljko, Todorovic, Dusan, Markovic, Vladimir, Ladjevac, Nevena, Zdravkovic, Natasa, Djurdjevic, Predrag, Arsenijevic, Nebojsa, Milovanovic, Marija, Arsenijevic, Aleksandar, Milovanovic, Jelena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139644/
https://www.ncbi.nlm.nih.gov/pubmed/35621683
http://dx.doi.org/10.3390/curroncol29050293
_version_ 1784714907314290688
author Todorovic, Zeljko
Todorovic, Dusan
Markovic, Vladimir
Ladjevac, Nevena
Zdravkovic, Natasa
Djurdjevic, Predrag
Arsenijevic, Nebojsa
Milovanovic, Marija
Arsenijevic, Aleksandar
Milovanovic, Jelena
author_facet Todorovic, Zeljko
Todorovic, Dusan
Markovic, Vladimir
Ladjevac, Nevena
Zdravkovic, Natasa
Djurdjevic, Predrag
Arsenijevic, Nebojsa
Milovanovic, Marija
Arsenijevic, Aleksandar
Milovanovic, Jelena
author_sort Todorovic, Zeljko
collection PubMed
description Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possible mechanisms of failures and expected developments.
format Online
Article
Text
id pubmed-9139644
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91396442022-05-28 CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings Todorovic, Zeljko Todorovic, Dusan Markovic, Vladimir Ladjevac, Nevena Zdravkovic, Natasa Djurdjevic, Predrag Arsenijevic, Nebojsa Milovanovic, Marija Arsenijevic, Aleksandar Milovanovic, Jelena Curr Oncol Review Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possible mechanisms of failures and expected developments. MDPI 2022-05-18 /pmc/articles/PMC9139644/ /pubmed/35621683 http://dx.doi.org/10.3390/curroncol29050293 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Todorovic, Zeljko
Todorovic, Dusan
Markovic, Vladimir
Ladjevac, Nevena
Zdravkovic, Natasa
Djurdjevic, Predrag
Arsenijevic, Nebojsa
Milovanovic, Marija
Arsenijevic, Aleksandar
Milovanovic, Jelena
CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
title CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
title_full CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
title_fullStr CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
title_full_unstemmed CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
title_short CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
title_sort car t cell therapy for chronic lymphocytic leukemia: successes and shortcomings
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139644/
https://www.ncbi.nlm.nih.gov/pubmed/35621683
http://dx.doi.org/10.3390/curroncol29050293
work_keys_str_mv AT todoroviczeljko cartcelltherapyforchroniclymphocyticleukemiasuccessesandshortcomings
AT todorovicdusan cartcelltherapyforchroniclymphocyticleukemiasuccessesandshortcomings
AT markovicvladimir cartcelltherapyforchroniclymphocyticleukemiasuccessesandshortcomings
AT ladjevacnevena cartcelltherapyforchroniclymphocyticleukemiasuccessesandshortcomings
AT zdravkovicnatasa cartcelltherapyforchroniclymphocyticleukemiasuccessesandshortcomings
AT djurdjevicpredrag cartcelltherapyforchroniclymphocyticleukemiasuccessesandshortcomings
AT arsenijevicnebojsa cartcelltherapyforchroniclymphocyticleukemiasuccessesandshortcomings
AT milovanovicmarija cartcelltherapyforchroniclymphocyticleukemiasuccessesandshortcomings
AT arsenijevicaleksandar cartcelltherapyforchroniclymphocyticleukemiasuccessesandshortcomings
AT milovanovicjelena cartcelltherapyforchroniclymphocyticleukemiasuccessesandshortcomings

Ejemplares similares